Go Pro
NASDAQ:SEPN

Septerna Q1 2025 Earnings Report

Septerna logo
$37.71 -0.34 (-0.89%)
Closing price 04:00 PM Eastern
Extended Trading
$37.66 -0.05 (-0.15%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Septerna EPS Results

Actual EPS
-$0.49
Consensus EPS
-$0.38
Beat/Miss
Missed by -$0.11
One Year Ago EPS
N/A

Septerna Revenue Results

Actual Revenue
$0.22 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Septerna Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

Septerna's Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Septerna Earnings Headlines

How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fraction of the cost? That's the core advantage options offer traders at every level. The Beginner's Guide to Options breaks down leverage, income strategies, and real trade examples in plain English — including a little-known approach many traders use to reduce costs and improve profit potential. Download your free copy before this offer expires.tc pixel
Septerna to Participate in Upcoming Investor Conferences
Septerna names Rajiv Patni as CMO
See More Septerna Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Septerna? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Septerna and other key companies, straight to your email.

About Septerna

Septerna (NASDAQ:SEPN) is a clinical-stage biopharmaceutical company focused on discovering and developing oral medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in numerous biological processes and are established targets for therapies across a range of diseases.

The company uses its proprietary Native Complex Platform to study GPCRs in their native state and identify small-molecule medicines for targets that have historically been difficult to address. Septerna’s investigational pipeline includes oral GPCR modulators, including SEP-786, an oral parathyroid hormone 1 receptor agonist being developed for the potential treatment of hypoparathyroidism.

Septerna was founded by scientists with expertise in GPCR biology and drug discovery and is headquartered in San Diego, California. The company has no marketed products and is advancing its candidates through clinical development and research activities intended to support treatments for patients in the United States and other global markets. Patrick Horn, Ph.D., serves as the company’s president and chief executive officer.

View Septerna Profile